William Blair Forecasts uniQure’s Q1 Earnings (NASDAQ:QURE)

uniQure (NASDAQ:QURE) – Research analysts at William Blair issued their Q1 2026 earnings estimates for uniQure in a report issued on Thursday, February 27th. William Blair analyst S. Corwin expects that the biotechnology company will post earnings per share of ($1.39) for the quarter. The consensus estimate for uniQure’s current full-year earnings is ($3.75) per share. William Blair also issued estimates for uniQure’s Q2 2026 earnings at ($1.41) EPS, Q3 2026 earnings at ($1.27) EPS and Q4 2026 earnings at ($1.22) EPS.

Several other research analysts have also issued reports on the company. StockNews.com upgraded uniQure to a “sell” rating in a research note on Wednesday, February 5th. Guggenheim restated a “buy” rating on shares of uniQure in a research report on Wednesday, December 11th. The Goldman Sachs Group lifted their target price on shares of uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a research note on Thursday, December 12th. Raymond James upgraded uniQure from an “outperform” rating to a “strong-buy” rating and increased their price target for the stock from $20.00 to $52.00 in a research report on Tuesday, December 10th. Finally, Cantor Fitzgerald boosted their price objective on uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 10th. One analyst has rated the stock with a sell rating, three have given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, uniQure currently has a consensus rating of “Moderate Buy” and an average price target of $38.89.

uniQure Trading Up 8.9 %

Shares of QURE opened at $13.15 on Friday. The stock has a 50 day simple moving average of $15.05 and a 200-day simple moving average of $9.79. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The stock has a market cap of $640.73 million, a PE ratio of -2.65 and a beta of 0.38. uniQure has a 1 year low of $3.73 and a 1 year high of $19.18.

Institutional Trading of uniQure

Institutional investors have recently bought and sold shares of the business. RTW Investments LP bought a new position in shares of uniQure in the 3rd quarter worth $49,000. China Universal Asset Management Co. Ltd. boosted its holdings in uniQure by 57.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after buying an additional 3,663 shares during the last quarter. Atria Investments Inc acquired a new position in shares of uniQure during the 3rd quarter worth about $53,000. Quarry LP bought a new stake in shares of uniQure in the 3rd quarter valued at about $58,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of uniQure in the 3rd quarter valued at approximately $69,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

Insider Activity

In related news, CFO Christian Klemt sold 2,916 shares of uniQure stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $11.32, for a total value of $33,009.12. Following the completion of the sale, the chief financial officer now directly owns 155,168 shares in the company, valued at $1,756,501.76. This trade represents a 1.84 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Matthew C. Kapusta sold 3,418 shares of the business’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the sale, the chief executive officer now directly owns 597,915 shares of the company’s stock, valued at $4,562,091.45. This represents a 0.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 55,915 shares of company stock valued at $588,112. Company insiders own 4.74% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.